Epigenetic modulation of resistance to chemotherapy?

Annals of Oncology

Volumn 18, Issue 9, 2007, Pages 1429-1430

  Brown, R ^a   Glasspool, R ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CA 125 ANTIGEN; CISPLATIN; CYTOTOXIC AGENT; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; VALPROATE MAGNESIUM; VALPROIC ACID;

ACETYLATION; CANCER HORMONE THERAPY; CLINICAL TRIAL; CPG ISLAND; DEMETHYLATION; DNA DETERMINATION; DNA MODIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG TOLERABILITY; EDITORIAL; ENZYME ACTIVITY; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METHYLATION; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PRIORITY JOURNAL; SOLID TUMOR;

CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34548378701     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm415     Document Type: Editorial

References (13)

1. Richardson A, Kaye SB. Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance, Drug Resist Updat 2005; 8: 311-321.
2. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006; 94(8): 1087-1092.
3. Costello JF, Fruhwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 132-138.
4. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005; 97: 1498-1506.
5. Cameron EE, Bachman KE, Myohanen S et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
6. Momparler RL, de Vos Haarlem D. 5-Aza-2′ Deoxycytidine: Preclinical and Clinical Studies. Haarlem, The Netherlands: PCH Publications 1990.
7. Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: Dose, duration, and patient selection. Nat Clin Pract Oncol 2005; 2 (Suppi 1): S24-S29.
8. Jones PA, Taylor SM. Cellular differentiation, cytidine analogues and DNA methylation. Cell 1981; 20: 89-93.
9. Schwartzmann G, Schunemann H, Gorini CNF et al. A phase I trial of cisplatin plus decltabine, a new DNA-hypomethylating agent, in patients with advanced solid tumours and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 2000; 18: 83-91.
10. Appleton K, Mackay HJ, Judson I et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours. J Clin Oncol 2007; In press.
11. Candelaria M, Gallardo-Rincón D, Arce C et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncoll 2007; 18: 1529-1538.
12. Samlowski WE, Leachman SA, Wade M et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23: 3897-3905.
13. Gormally E, Caboux E, Vineis P, Hainaut P. Circulation free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mutat Res 2007; 635(2-3): 105-117.